NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'

Published 24/06/2024, 19:08
© Reuters.  Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company \'Very Likely\'
LLY
-
NVO
-

Benzinga - by Surbhi Jain, .

Eli Lilly And Co (NYSE:LLY) might see a significant boost due to supply issues at competitor Novo Nordisk A/S (NYSE:NVO), according to Reddit user serkankster.

$LLY up potential

byu/serkankster instocks

It was noted that Eli Lilly’s weight loss drug Zepbound resolved previous supply issues, especially in major cities. The Redditor highlighted recent fires at Novo Nordisk’s facilities could further limit their supply, potentially benefiting Eli Lilly.

Redditor serkankster commented, “The revenues of $LLY has mostly been driven by the GLP-1 weight loss drug which was experiencing a lot of supply issues.” The user also speculated on a potential stock split for Eli Lilly, driven by its strong performance and high share price nearing $1,000.

Another user, LetsPlay30k, echoed this sentiment, suggesting a stock split is “very likely.”

Comment

byu/serkankster from discussion

instocks

Also Read: Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions

While some Redditors, like Electrical-Judge3789 and 3ebfan, clarified the fires at Novo Nordisk were not in their manufacturing areas, serkankster mentioned the fires affected a factory site under construction and two office buildings.

They also noted Novo Nordisk’s recent acquisition of Catalent, a major contract manufacturer for Eli Lilly, could impact its supply chain.

https://www.reddit.com/r/stocks/comments/1dn5e2k/comment/la0xh4u/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

Eli Lilly’s potential was further supported by cryptovorrection69, who highlighted an upcoming FDA approval for an Alzheimer’s drug. It “could give them a sizable jump when announced,” he commented.

Another user, twostroke1, mentioned Eli Lilly's ongoing $10 billion plant construction in Indiana, set to increase their weight loss drug supply by 2026. The user is bullish on this development: “That's when the real supply will skyrocket. Whether investors are pricing this in already or not is anyone's guess. But looking at the performance of Lilly over the past decade, I'd be very hesitant to bet against it,” he said.

Reddit users are closely watching these developments, with many expressing optimism about Eli Lilly’s stock performance and supply capabilities.

Read Next: Novo Nordisk’s Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition

Photos: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.